The Cuban company Heber Biotec and the U.S. company Mercurio Biotec join efforts to bring Heberprot-P therapy to patients who suffer from diabetic foot ulcer (DFU) in the United States, upon approval from the U.S. Food and Drug Administration (FDA).
According to the press note released by the entrepreneurial group BioCubaFarma, the Cuban therapy is expected to lower in more than half the current figure of risk of diabetic foot ulcer-related amputations in the United States, due to the successful history of the product and the commitment given by Mercurio and Heber.
Nearly one million of U.S. patients debut with DFU at year. This complication increases the risk of lower limb amputations. In five years the number of amputees in the U.S., has increased from 73 000 to 85 000, having negative consequences for families and health systems and causing social and economic damages.